IPOX® Associate Muehlbauer highlighted the growing momentum in the space technology sector following HawkEye 360’s U.S. IPO filing. He noted that while the anticipated SpaceX listing acts as a massive thematic catalyst, it could simultaneously divert investor focus from smaller issuers. Muehlbauer observed that HawkEye is strategically entering the public market during a favorable issuance window to manage debt from its recent acquisition of Innovative Signal Analysis, leveraging its 74% revenue jump and transition to profitability to attract disciplined investors.

IPOX® Associate Muehlbauer was featured in a recent Reuters article discussing the drone manufacturer AEVEX’s upcoming $2.35 billion IPO. Providing expert analysis on the growing investor appetite for defense technologies, he highlighted how rising global military spending has created a new defense 'supercycle.' He noted that conflicts in Ukraine and the Middle East underscore the critical role of modern unmanned systems, driving thematic investor interest in the rapidly expanding global drone sector.

IPOX® Associate Muehlbauer was featured in a Bloomberg article discussing the challenges facing European IPOs as lock-up periods expire. With many 2025 listings trading significantly below their offer prices, Muehlbauer noted that while selling at a discount can "lock in a disappointing valuation," strategic follow-on sales may ultimately benefit companies by improving liquidity and reducing market overhang. His analysis highlights the complex balancing act for investors navigating a thawing European equity market and shifting valuation benchmarks.

A recent Reuters article explores how SpaceX’s anticipated $75 billion IPO could overshadow other listings and absorb a massive share of investor capital, potentially delaying a broader U.S. IPO market revival until 2027. IPOX® CEO Josef Schuster provided expert commentary on the current listings environment, cautioning that even high-profile debuts cannot escape current market realities. He emphasized that the U.S. remains a buyer’s market, requiring even strong candidates in hot sectors to demonstrate pricing flexibility to achieve IPO success.

National Healthcare Properties has filed for a U.S. IPO, becoming the latest real estate investment trust (REIT) to enter the public markets this year. Amid market volatility and caution regarding AI-driven disruptions, defensive sectors like REITs are gaining traction. IPOX® CEO Josef Schuster notes that the IPO window remains wide open for U.S. firms insulated from economic shifts and tech valuation resets. He highlights healthcare REITs as a bright spot offering attractive dividend yields, uncorrelated stability, and strong recent performance.